First PCV-2 / Mycoplasma hyopneumoniae vaccine combination registered in the European Union
Ingelheim, Germany, 8 July 2010 - The EU Commission has approved the simultaneous use of the pig vaccines Ingelvac CircoFLEX® and Ingelvac MycoFLEX® in the European Union. Boehringer Ingelheim will market this unique vaccine concept under the name FLEXcombo®. The simultaneous administration of both vaccines represents an innovation in pig health management. Now protection against two of the most prominent and costly pig diseases, Porcine Circovirus Disease (PCVD) and Enzootic Pneumonia, can be achieved with a single injection instead of up to four injections. Today an average of more than 70% of European pigs receive vaccines for these two diseases.
The combined use of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® is already registered and widely used in North America and Asia. It is globally the first and only product combination of its kind. “We are very proud that we can now also supply veterinarians and farmers within the European Union with the latest innovation: the simultaneous use of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® . It will help them tremendously in reducing the number of injections to pigs, in supporting the well-being of their animals and the farm economics by saving a substantial amount of labour” comments Dr. Joachim Hasenmaier, Head of Corporate Animal Health at Boehringer Ingelheim.
About Ingelvac CircoFLEX®
Ingelvac CircoFLEX® is the leading PCV-2 vaccine on
the world market. The brand is registered for use as a single
vaccination for pigs around weaning against the clinical signs
associated with porcine circovirus type 2 (PCV2) including
mortality, weight loss and lesions in lymphoid tissues. It is based
on ImpranFLEX®, a unique adjuvant platform which was
specifically designed for effective and safe mixing within the
FLEXcombo® concept.
About Ingelvac MycoFLEX®
Ingelvac MycoFLEX® is the leading Mycoplasma hyopneumoniae
(Enzootic Pneumonia) vaccine in North America and was launched in
Europe in late 2009/ early 2010. The vaccine is registered for the
active immunisation of pigs aged three weeks and more to reduce
lung lesions following infection with Mycoplasma hyopneumoniae. It
is also based on ImpranFLEX®, the unique adjuvant platform
known from Ingelvac CircoFLEX®.
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the
world’s 15 leading pharmaceutical companies. Headquartered in
Ingelheim, Germany, it operates globally with 142 affiliates in 50
countries and more than 41,500 employees. Since it was founded in
1885, the family-owned company has been committed to researching,
developing, manufacturing and marketing novel products of high
therapeutic value for human and veterinary medicine.
In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro
while spending 21% of net sales in its largest business segment
Prescription Medicines on research and development.
